Demographic and Clinical Characteristics of the Study Patient Cohort_
| Full cohort N=150 | Frequency | ||
|---|---|---|---|
| Demographic parameters | n | (%) | |
| Age group | < 40 years | 2 | 1.3 |
| 41-60 years | 30 | 20.0 | |
| > 61 years | 118 | 78.7 | |
| Gender | Male | 90 | 60.0 |
| Female | 60 | 40.0 | |
| Clinical parameters | |||
| Indication for clopidogrel therapy | STEMI/NSTEMI* | 65 | 43.3 |
| Other | 85 | 56.7 | |
| Co-morbidities | One | 97 | 64.7 |
| More than one | 53 | 35.3 | |
| Diabetes mellitus | With | 65 | 43.3 |
| Without | 85 | 56.7 | |
| Hypertension | With | 101 | 67.3 |
| Without | 49 | 32.7 | |
| Dyslipidemia | With | 6 | 4.0 |
| Without | 144 | 96.0 | |
Distribution of CYP2C19*2 Allele, Genotype, and Phenotype Frequencies in the Patient Population (N=150), According to Age, Gender, and the Most Common CVD Risk Factors_
| CYP2C19*2 polymorphism [rs4244285] | Genotype (phenotype)# | Allele | ||||
|---|---|---|---|---|---|---|
| *1/*1 n (%) | *1/*2 n (%) | *2/*2 n (%) | *2 n (%) | *1 n (%) | ||
| Group age | < 40 years | 1 (50) | 1 (50) | 0 (0) | 1 (25) | 3 (75) |
| 41-60 years | 18 (60) | 10 (33.33) | 2 (6.67) | 14 (23.33) | 46 (76.67) | |
| > 61 years | 80 (67.80) | 33 (27.96) | 5 (4.24) | 43 (18.22) | 193 (81.78) | |
| Gender | Male | 61 (67.78) | 25 (27.78) | 4 (4.44) | 33 (18.33) | 147 (81.67) |
| Female | 38 (63.33) | 19 (31.67) | 3 (5) | 25 (20.83) | 95 (79.17) | |
| Diabetes mellitus | With | 45 (69.23) | 16 (24.62) | 4 (6.15) | 24 (18.46) | 106 (81.54) |
| Without | 54 (63.53) | 28 (32.94) | 3 (3.53) | 34 (20) | 136 (80) | |
| Hypertension | With | 67 (66.34) | 29 (28.71) | 5 (4.95) | 39 (19.31) | 163 (80.69) |
| Without | 32 (65.31) | 15 (30.61) | 2 (4.08) | 19 (19.39) | 79 (80.61) | |
| Dyslipidemia | With | 4 (66.67) | 2 (33.33) | 0 (0) | 16 (61.54) | 10 (38.46) |
| Without | 95 (65.97) | 42 (29.16) | 7 (4.87) | 42 (15.33) | 232 (84.67) | |
Association of CYP2C19*2 polymorphism and risk for CVD in Kosovo population_
| Model of Statistical Analysis | Patients (N=150) | Healthy population# (N=234) | OR | 95 % CI | p-value | ||
|---|---|---|---|---|---|---|---|
| n | Frequency (%) | n | Frequency (%) | ||||
| Co – dominant | |||||||
| *1/*1 (NM) | 99 | 66 | 178 | 76.07 | 1.00 | ||
| *1/*2 (IM) | 44 | 29.33 | 51 | 21.79 | 1.295 | 0.991 - 1.694 | 0.067 |
| *2/*2 (PM) | 7 | 4.67 | 5 | 2.14 | 1.632 | 0.896 - 2.701 | 0.112 |
| Dominant | |||||||
| *1/*1(NM) | 99 | 66 | 178 | 76.07 | 1.00 | ||
| *2/*2+*1/*2 (PM+IM) | 51 | 34 | 56 | 23.93 | 1.334 | 1.035 - 1.719 | 0.031 |
| Allelic | |||||||
| *1 allele | 242 | 80.67 | 407 | 86.97 | 1.00 | ||
| *2 allele | 58 | 19.33 | 61 | 13.03 | 1.307 | 1.06 - 1.612 | 0.018 |
Distribution of the CYP2C19*2 Allele and Genotype/Phenotype Frequencies in the Patient Population_
| CYP2C19*2 polymorphism [rs4244285] | Patient cohort (N=150) | Frequency (%) | |
|---|---|---|---|
| n | observed | expected | |
| Genotype (phenotype)# | |||
| *1/*1 (NM) | 99 | 66.0 | 65.07 |
| *1/*2 (IM) | 44 | 29.33 | 31.19 |
| *2/*2 (PM) | 7 | 4.67 | 3.74 |
| Allele | |||
| *1 | 242 | 80.67 | NA |
| *2 | 58 | 19.33 | |